Researchers and clinicians with an interest in insulin resistance, diabetes, and cardiovascular disease are invited to join the MASLD Study Group.
MASLD membership provides access to scientific meetings and webinars, collaborative research opportunities, and MASLD-related publications and study initiatives.
MASLD to contribute to and engage with a European network dedicated to advancing research in insulin resistance. Please send your request to the following email: lucrecia.mota@med.unipi.it
Joint EGIR-MASLD Study Group Meeting, Pisa, Italy- December 1-3, 2025
03-PNPLA3 p.I148M variant affects lipid droplets number and composition in patient-derived liver organoids
Elia Casirati - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Transfusion Medicine and Hematology, Milano, Italy
MASLD-EGIR Study Group Meeting Lille, France- December 4-6, 2024.
MASLD Pharmacological inhibition of fructose metabolism reduces liver fat and improves insulin sensitivity in participants with MASLD
Evi Koene - Department of Nutrition and Movement Science, NUTRIM research school, Maastricht University, Maastricht, Netherlands.
NAFLD Study Group Annual Webinar - 24 October 2023
Human resident liver macrophages protect against metabolic stress in obesity
Emely Barrebystrong - Karolinska Institutet, Sweden.
NAFLD Study Group Abstract Webinar – 23 November 2022
Systemic soluble TREM2 levels reflect the recruitment of TREM2+ macrophages to areas of hepatic fibrosis to limit NASH,
Tim Hendrikx - Department of Laboratory Medicine, KILM, Medical University Vienna, Vienna, Austria.
NAFLD Study Group Abstract Webinar - 9 December 2021
Impact of hepatic steatosis on myocardial glucose uptake and insulin sensitive tissues using PET18FDG in individuals without diabetes.
Anne Marie Carreau - Médecine, Axe Endocrinologie et Néphrologie, Centre de Recherche CHU de Québec Université Laval, Quebec, Canada.
NAFLD Study Group - virtual meeting Abstracts - 11 December, 2020
TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models,
Miriam Longo - General Medicine and Metabolic Diseases; Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.